ESR1 and breast carcinoma: Targeting the ER by selective ER modulators (SERM) or reducing estradiol with aromatase inhibitors (AI) is the main treatment of ER+ breast cancer, but endocrine therapy resistance eventually occurs, which leads to disease progression.